Gufic Biosciences | GUFICBIO | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
| 55 | 73 | 37 | 108 | 132 |
Short-term investment |
| 0 | 0 | 0 | 0 | 0 |
Accounts receivables |
| 530 | 810 | 1,032 | 1,012 | 1,245 |
Inventories |
| 630 | 939 | 943 | 1,092 | 944 |
Deferred income taxes |
| 0 | 0 | 0 | 0 | 0 |
Other current assets |
| 226 | 149 | 314 | 422 | 285 |
Total current assets |
| 1,442 | 1,970 | 2,325 | 2,635 | 2,606 |
Gross property plant... |
| 220 | 222 | 337 | 318 | 938 |
Accumulated Depriciat... |
| 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
| 220 | 222 | 337 | 318 | 938 |
Work in Progress |
| 0 | 21 | 0 | 306 | 134 |
Miscellaneous Investment |
| 83 | 57 | 0 | 101 | 116 |
Deferred income taxes |
| 0 | 25 | 7 | 4 | 0 |
Intangible assets |
| 0.11 | 1 | 3 | 6 | 4 |
Goodwill |
| 0 | 0 | 0.22 | 0 | 0 |
Other long-term assets |
| 33 | 65 | 123 | 193 | 123 |
Total non-current assets |
| 337 | 390 | 470 | 928 | 1,315 |
Total assets |
| 1,778 | 2,361 | 2,795 | 3,562 | 3,921 |
Short-term debt |
| 470 | 692 | 864 | 894 | 163 |
Accounts Payable... |
| 397 | 745 | 778 | 1,086 | 1,130 |
Provisions |
| 78 | 36 | 0 | 93 | 46 |
Taxes Payable |
| 0 | 26 | 42 | 8 | 16 |
Deferred Revenues |
| 0 | 0 | 0 | 0 | 0 |
Capital Leases |
| 0 | 0 | 0.38 | 34 | 34 |
Other current liabilities |
| 208 | 174 | 179 | 130 | 248 |
Total current liabilities |
| 1,153 | 1,673 | 1,863 | 2,246 | 1,637 |
Long-term debt |
| 68 | 83 | 113 | 179 | 354 |
Investments Liabilities |
| 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
| 5 | 0 | 0 | 0 | 15 |
Provisions |
| 23 | 23 | 19 | 69 | 102 |
Capital Leases |
| 0 | 0 | 0 | 62 | 28 |
Other longterm liabilities |
| 80 | 48 | 47 | 47 | 50 |
Total non-current liabilities |
| 176 | 153 | 178 | 358 | 550 |
Total liabilities |
| 1,329 | 1,826 | 2,042 | 2,604 | 2,186 |
Share Capital |
| 77 | 77 | 78 | 78 | 97 |
Share premium |
| 0 | 0 | 0 | 0 | 0 |
Retained earnings |
| 372 | 458 | 659 | 881 | 1,637 |
Accumulated other equity |
| 0 | 0 | 16 | 0 | 0 |
Preferred Stock |
| 0 | 0 | 0 | 0 | 0 |
Minority Interest |
| 0 | 0 | 0 | 0 | 0 |
Total Equity |
| 449 | 535 | 753 | 959 | 1,734 |
Total Liabilities and Equity |
| 1,778 | 2,361 | 2,795 | 3,562 | 3,921 |
Cash per Share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |